大理药业(603963) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥36,887,280.13, representing a decrease of 7.36% compared to the same period last year[6]. - The net profit attributable to shareholders was -¥2,551,643.71, with a basic earnings per share of -¥0.0116[6]. - Total operating revenue for Q1 2023 was CNY 36,887,280.13, a decrease of 7.3% compared to CNY 39,816,703.15 in Q1 2022[17]. - Net loss for Q1 2023 was CNY -2,551,643.71, an improvement from a net loss of CNY -3,207,503.31 in Q1 2022, indicating a 20.4% reduction in losses[18]. - Gross profit margin for Q1 2023 was approximately -10.0%, compared to a margin of -7.0% in Q1 2022, highlighting a decline in profitability[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥490,390,642.70, down 2.60% from the end of the previous year[7]. - Total assets as of Q1 2023 were CNY 490,390,642.70, down from CNY 503,486,467.80 at the end of Q1 2022, a decline of 2.2%[17]. - Total liabilities for Q1 2023 were CNY 91,785,928.97, compared to CNY 102,330,110.36 in Q1 2022, representing a decrease of 10.3%[16]. - The total liabilities remained stable at CNY 101,560,127.69 as of January 1, 2023[24]. - Deferred tax liabilities were reported at 334,982.51, down from 446,557.60[25]. Cash Flow - The cash flow from operating activities was -¥5,206,773.92, primarily due to a decrease in cash paid for goods[9]. - In Q1 2023, the cash inflow from operating activities was CNY 40,925,167.74, a decrease of 1.56% compared to CNY 41,574,777.56 in Q1 2022[20]. - The net cash flow from operating activities was -CNY 5,206,773.92, an improvement from -CNY 6,173,987.51 in the same period last year[20]. - The cash inflow from investment activities totaled CNY 102,285,700.52, with a net cash flow of CNY 19,950,157.84, compared to a net outflow of -CNY 108,271,432.96 in Q1 2022[21]. - The cash paid for taxes increased significantly to CNY 6,791,496.84 in Q1 2023, compared to CNY 3,653,736.94 in Q1 2022, marking an increase of about 86.5%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,216[10]. - The top shareholder, Yang Junxiang, holds 24.20% of the shares, totaling 53,172,200 shares[11]. - The company's total equity attributable to shareholders was CNY 398,604,713.73 in Q1 2023, slightly down from CNY 401,156,357.44 in Q1 2022, a decrease of 0.4%[17]. Research and Development - Research and development expenses for Q1 2023 were CNY 151,998.65, significantly lower than CNY 347,576.35 in Q1 2022, a decrease of 56.3%[18]. - The company did not report any significant new product developments or market expansion strategies during this quarter[13]. Accounting Changes - The company has implemented new accounting standards starting January 1, 2023, affecting the recognition of deferred tax assets and liabilities[21].